Marksans Pharma Limited (NSE:MARKSANS)
India flag India · Delayed Price · Currency is INR
309.15
+5.40 (1.78%)
Nov 9, 2026, 12:25 PM IST

Marksans Pharma Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
5,5984,1793,8063,1372,6631,868
Depreciation & Amortization
1,052982.39830.02740.55518.53447.76
Other Amortization
3.933.933.842.15--
Loss (Gain) From Sale of Assets
1.470.640.33-0.942.64-
Loss (Gain) From Sale of Investments
-136.6416.9833.12-43.63108.02-56.23
Stock-Based Compensation
33.3833.38----
Provision & Write-off of Bad Debts
293.36218.5883.2851.57143.6126.32
Other Operating Activities
232.77-229.08-281.96-320.7152.89-186.4
Change in Accounts Receivable
-819-313.9-777.9-371.67-275.18-1,039
Change in Inventory
213.14-387.25-1,955-1,127-448.5-178.49
Change in Accounts Payable
-----284.79
Change in Other Net Operating Assets
572.0576.58324.83236.48-390.97-173.98
Operating Cash Flow
7,0454,5812,0672,3042,374992.57
Operating Cash Flow Growth
244.10%121.68%-10.30%-2.95%139.19%-44.42%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-1,034-1,305-1,729-2,088-536.31-463.3
Sale of Property, Plant & Equipment
7.159.7712.498.543.770.34
Cash Acquisitions
-847.01----266.1-
Investment in Securities
-1,938-1,450888.64-259.48-1-428.55
Other Investing Activities
253.28262.47337.97930.92-1,79247.6
Investing Cash Flow
-3,559-2,483-490.09-1,408-2,592-843.91

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-65.06--52.96225.52
Total Debt Issued
62.1665.06--52.96225.52
Short-Term Debt Repaid
---60.06-124.97--
Long-Term Debt Repaid
--383.96-295.65-284-207.73-155.17
Lease Payments
-456.18-383.96-295.65-284-207.73-155.17
Total Debt Repaid
-503.67-383.96-355.71-408.97-207.73-155.17
Net Debt Issued (Repaid)
-441.51-318.9-355.71-408.97-154.7770.35
Repurchase of Common Stock
-----321.14-
Common Dividends Paid
-407.85-362.53-271.9-226.58-101.71-105.83
Dividends Paid
-407.85-362.53-271.9-226.58-101.71-105.83
Other Financing Activities
-26.79-27.85-23.85-51.722,606830.59
Financing Cash Flow
-876.15-709.28-651.46-687.271,978795.11

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
-5.77-5.79--0.02-
Net Cash Flow
2,6041,384925.09208.41,760943.77

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
6,0103,276337.45215.691,838529.27
Free Cash Flow Growth
1637.61%870.81%56.45%-88.26%247.24%-59.95%
Free Cash Flow Margin
17.72%11.10%1.29%0.99%9.92%3.55%
Free Cash Flow Per Share
13.277.230.740.484.421.29
Levered Free Cash Flow
3,445718.53-699.7-510.23661.16-227.75
Unlevered Free Cash Flow
3,608869.31-626.82-440.21699.26-191.87
Free Cash Flow After Leases
5,5542,89241.8-68.311,630374.1

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
26.7927.8523.8551.7260.6680.96
Cash Income Tax Paid
1,7521,3971,2591,223630.14728.59
Change in Working Capital
-33.81-624.57-2,408-1,262-1,115-1,107